Risk of the Development of Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Rheumatoid Arthritis

Abstract

), PLT count (p<0.001), and alanine aminotransferase values (p<0.05) (r=0.956). Conclusion: Our study highlights that patients with both MAFLD and RA face a heightened risk of fibrosis progression compared with those without RA. While existing literature acknowledges MAFLD’s association with liver fibrosis, there is a scarcity of research on RA’s influence in this context. Our findings emphasize RA as an additional risk factor for liver fibrosis, particularly among patients with MAFLD. Consequently, liver fibrosis is more prevalent in patients with MAFLD and RA.